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Abstract
Epigenetic remodeling is one of the major features of the aging process. We recently demonstrated that DNA methylation of ELOVL2 and FHL2 
CpG islands is highly correlated with age in whole blood. Here we investigated several aspects of age-associated hypermethylation of ELOVL2 
and FHL2. We showed that ELOVL2 methylation is significantly different in primary dermal fibroblast cultures from donors of different 
ages. Using epigenomic data from public resources, we demonstrated that most of the tissues show ELOVL2 and FHL2 hypermethylation 
with age. Interestingly, ELOVL2 hypermethylation was not found in tissues with very low replication rate. We demonstrated that ELOVL2 
hypermethylation is associated with in vitro cell replication rather than with senescence. We confirmed intra-individual hypermethylation 
of ELOVL2 and FHL2 in longitudinally assessed participants from the Doetinchem Cohort Study. Finally we showed that, although the 
methylation of the two loci is not associated with longevity/mortality in the Leiden Longevity Study, ELOVL2 methylation is associated with 
cytomegalovirus status in nonagenarians, which could be informative of a higher number of replication events in a fraction of whole-blood 
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In our aging society, the availability of reliable biomarkers of aging is 
important for an efficient and well-prioritized management of health 
services and resources to patients. A biomarker of aging is defined 
as “a biological parameter of an organism that either alone or in 
some multivariate composite will, in the absence of disease, better 
predict functional capability at some late age than will chronological 
age” (1), and its ideal features have been extensively drawn up (2,3). 
A major requisite of a biomarker of aging is that it should have a 
good correlation with the chronological age of the individuals in a 
population, and in addition reflect the inter-individual heterogene-
ity in the aging rates of the individuals, that is, their biological age. 
Biological age is a difficult concept to define, as an individual could 
display a youthful phenotype for some health parameters but not 
for others. However, it could be agreed that the ultimate readout of 
successful biological aging is a long life span (longevity) or a long 
(disease-free) health span. This means that appropriate human study 
designs such as middle aged and elderly prospective populations as 
well as family studies are essential to demonstrate the effectiveness 
of a biomarker of aging (4). To date, although a number of biological 
parameters, such as leukocyte telomere length, deletion of mtDNA, 
protein modifications, and changes in the expression of specific pro-
teins, have been proposed as potential biomarkers of aging (5,6), 
their effectiveness remains to be proven.
Cross-sectional and longitudinal studies have demonstrated the 
profound remodeling of DNA methylation patterns that occurs in 
the human genome as a function of chronological age in several tis-
sues (reviewed in reference (7)). Based on these results, reliable age 
predictors were defined by combining CpG sites whose methylation 
status was age associated (8–11). Besides the strong correlation with 
age, two of these epigenetic age predictors have recently been associ-
ated with mortality (12,13) and longevity (14), posing them as poten-
tial markers of biological aging. The first age predictor (9) combines 
71 CpG sites from the Infinium HumanMethylation450 BeadChip 
(Infinium 450k) microarray, whose methylation status in blood var-
ies with aging in a cohort of 656 participants aged 19 to 101 years. 
The second age-associated epigenetic signature (10) was built starting 
from several DNA methylation profiles available in public databases 
and includes 353 CpG sites from the Infinium HumanMethylation27 
BeadChip (Infinium 27k) microarray (which are also included in 
the Infinium 450k microarray). This epigenetic clock works in most 
human cell types and tissues and is correlated not only with mortality 
but also with physical and cognitive fitness (15).
Currently there is a lack of cost-effective methods to analyze 
several dozens of CpG sites, such as those included in Hannum’s 
and Horvath’s epigenetic clocks, and the most affordable approach 
is to use the Infinium 450k microarray. The definition of epigenetic 
biomarkers including a smaller number of CpG probes, assessable 
by high-throughput methods such as EpiTYPER MassARRAY or 
pyrosequencing, would allow for translation of these findings toward 
actual clinical applications. Along this line, Wagner and co-authors 
tested blood predictors of age including few or single Infinium CpG 
probes (11). Compared with Horvath’s and Hannum’s clocks, these 
simple biomarkers were weakly correlated with chronological age, 
probably also because they are more affected by technical variations 
between independent microarray data sets (16). In addition, their 
association with mortality, although statistically significant in some 
data sets, was rarely reproducible in independent cohorts (12,16).
In one of the first studies that used the Infinium 450k platform 
to analyze age-associated changes in blood DNA methylation (17), 
we identified two genomic regions, localized within the CpG islands 
of the promoters of ELOVL2 and FHL2 genes, whose methylation 
status was highly correlated with age. These findings were later 
confirmed by similar studies (18–22). Both ELOVL2 and FHL2 
showed continuous increase in methylation levels with age, with 
methylation values ranging from 7% to 91% for ELOVL2 and from 
12% to 53% for FHL2. The CpGs identified by our group within 
ELOVL2 and FHL2 are not part of Horvath’s epigenetic clock, 
which was built using the CpG probes common to the Infinium 
HumanMethylation27 BeadChip and the Infinium450k, while are 
part of Hannum’s age predictor.
In this article, we investigated the potential of ELOVL2 and 
FHL2 as simple epigenetic biomarkers of chronological and biologi-
cal aging. To this aim, we first confirmed the correlation of ELOVL2 
and FHL2 methylation with age in different tissues and cell types, 
using also in vitro models of cell replication and senescence. Then, 
we measured ELOVL2 and FHL2 methylation in whole blood from 
a longitudinal cohort that is part of the Doetinchem Cohort Study. 
Finally, we evaluated for the first time the association of whole-
blood ELOVL2 and FHL2 methylation with familial longevity, mor-
tality, and other biological parameters in the Leiden Longevity Study 
(LLS). This cohort was established to identify biomarkers related to 
familial longevity (23,24) and includes long-lived siblings, their off-
spring, and the spouses of the offspring. Collectively these analyses 
represent a first step to disentangle the mechanisms that underlie 
ELOVL2 and FHL2 age-dependent hypermethylation and to evalu-
ate their validity as biomarkers of aging.
Methods
Study Population
For the comparison of ELOVL2 and FHL2 DNA methylation 
between blood and granulocytes, we used samples from 92 par-
ticipants aged 22 to 98  years (mean age  =  55  years). The cohort 
included healthy volunteers recruited between 2004 and 2005 in 
Bologna and neighboring districts. Informed consent, approved by 
the Medical Ethics Committee of the S. Orsola-Malpighi Polyclinic 
(Bologna, Italy), was obtained from all participants.
Longitudinal assessment of ELOVL2 and FHL2 DNA meth-
ylation in whole blood was performed on 19 participants from the 
Doetinchem Cohort Study, a population-based prospective study on 
the impact of (changes in) lifestyle factors and biological risk fac-
tors on various aspects of health and well-being of Dutch adults. 
In 1987–1991 (t1), self-completed questionnaires were collected 
and a physical examination was performed on a random sample of 
12,405 men and women aged 20–59 years (response rate 62%) from 
the town of Doetinchem. Of those, a two-third random sample of 
7,768 participants was reinvited to be examined in 1993–1997 (t2, 
n = 6,113), 1998–2002 (t3, n = 4,916), 2003–2007 (t4, n = 4,520), 
and 2008–2012 (t5, n = 4,017). The response rate for the second, 
third, fourth, and fifth round was 75% and more. Informed con-
sent was obtained from all participants, and ethical clearance was 
obtained from the Medical Ethics Committees of the Netherlands 
Organization of Applied Scientific Research. Further details of the 
study design have been described elsewhere (25). The 19 partici-
pants assessed for ELOVL2 and FHL2 methylation (9 women and 
10 men) were a selection of healthy volunteers (baseline age range: 
22–57 years) whose body mass index remained below 25 kg/m2 dur-
ing the entire follow-up (t1–t5). Details of this group are reported in 
Supplementary Table 1.
For the LLS, long-lived siblings of European descent were 
recruited together with their offspring and the spouses of the off-
spring. Families were included if at least two long-lived siblings were 
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alive and fulfilled the age criterion of 89 years or older for men and 
91  years or older for women, representing less than 0.5% of the 
Dutch population in 2001 (26). In total, 944 long-lived siblings with 
a mean age of 94 years (range 89–104), 1,671 offspring (61 years, 
39–81), and 744 spouses thereof (60 years, 36–79) were included. 
For this study, we removed the individuals for whom DNA was not 
available for measurement (n = 96), the identity was not confirmed 
after genotyping (n = 81), or ELOVL2 and FHL2 were not success-
fully measured (n = 8), leaving 872 nonagenarians, 1,574 offspring, 
and 728 spouses for analysis. White blood cell (WBC) counts were 
measured using the Sysmex XE-2100 (TOA Medical Electronics) 
(27). Cytomegalovirus (CMV) serostatus was determined on blind 
samples using the CMV-IgG-ELISA PKS assay (Medac GmbH) (28).
Publicly Available DNA Methylation Profiles of 
Healthy Tissues
We considered all DNA methylation data sets available on October 
2015 in GEO DataSets repository (http://www.ncbi.nlm.nih.gov/gds) 
that fulfilled the following requirements: (i) generated with Infinium 
450k platform (GPL13534); (ii) analyzing healthy human tissues; 
and (iii) including information regarding the age of the involved par-
ticipants (attribute name “age” or “age (yrs)” or “age (years)” or 
“age (y)”). The list of selected data sets is reported in Supplementary 
Table 2. Beta values were extracted for the CpG probes reported in 
Supplementary File 1.
Cell Cultures
Primary dermal fibroblasts (DFs) were established from biopsies 
of sun-protected forearm skin from healthy donors. All the donors 
gave written informed consent to the biopsy. In total, 10 participants 
were studied: 3 young donors (3 women, age range: 30–31 years), 3 
middle-aged donors (2 men and 1 women, age range: 58–68 years), 
and 4 centenarian donors (4 women, age range: 100–105 years). DFs 
were cultured in Dulbecco’s modified Eagle’s medium (DMEM, Life 
Technologies) containing 25 mM of glucose supplemented with 10% 
fetal bovine serum (FBS, Life Technologies) at 37  °C in 5% CO2 
humidified atmosphere. In addition, the medium contained 100 U/
mL of penicillin, 100 µg/mL of streptomycin (Life Technologies), and 
4 mM of glutamine.
Human embryonic diploid lung fibroblast cells (LF1) were grown 
at 37  °C in 5% CO2 and 2.5% O2 atmosphere in F-10 nutrient 
medium (Thermo Scientific) supplemented with 15% FBS, penicillin, 
streptomycin, and l-glutamine (29). Cells were serially passaged at 
1:4 dilutions when reaching 80%–90% confluence. In early passage 
cultures, the time between passages was constant at approximately 
3  days; as culture approached senescence, it increased up to 2–3 
weeks. At this point, cells were passaged upon reaching 80% conflu-
ence at 1:2 dilution. Under these experimental conditions, cultures 
were monitored by microscopic observation every 2–3 days to assess 
cell division. Cell cultures that could not reach 80% confluence were 
considered senescent. Subsequently, cultures were incubated further 
up to 4 months with replating at 4, 8, 12, and 16 weeks in senes-
cence. Experiments were performed with cells harvested at early 
passages, after 8 weeks in senescence (senescent) and 16 weeks in 
senescence (deep senescent).
Measurement of ELOVL2 and FHL2 Methylation
The EpiTYPER assay (Sequenom) was used to quantitatively measure 
the methylation level of individual CpG sites in ELOVL2 and FHL2 
CpG islands, as previously described (17). The amplified regions 
were chr6:11,044,680-11,045,053 (GRCh37/hg19) within ELOVL2 
locus and chr2:106,015,678-106,016,008 (GRCh37/hg19) within 
FHL2 locus. ELOVL2 and FHL2 amplicons included respectively 
probes: cg16867657, cg24724428, cg21572722, cg16323298 and 
cg06639320, cg22454769, cg24079702, cg26344233, cg06907053 
from the Infinium 450k design (Supplementary Figure 1). PCR prod-
ucts were processed following manufacturer’s instructions to meas-
ure the percentage of methylation of single CpG sites or of group 
of adjacent CpG sites (indicated as CpG units), depending on the 
genomic sequence. For each locus, CpG units with missing values 
in more than 20% of the samples were removed, as well as samples 
with missing values in more than 20% of the CpG units.
Statistical Analyses
For each CpG unit, correlations between methylation level 
(measured as β value in data from Infinium450k data sets and 
as percentage of methylation in data from EpiTYPER assay) and 
chronological age or replicative passage were calculated using 
Spearman’s correlation.
To study longitudinal changes in ELOVL2 CpG_11.12.13.14 
and FHL2 CpG_9.10 methylation in the Doetinchem Cohort Study, 
we used the R package lmerTest to construct mixed models with 
subject-specific random effects for the intercept and the slope. 
Importantly, this approach allows to account for missing data in our 
data set (Supplementary Table 1). For both the CpG units, we first 
constructed a model testing the association between methylation and 
time, expressed as years, which included an interaction term (Time × 
Age at the recruitment) to estimate the effect of the age at the recruit-
ment on the rate of change of DNA methylation (slope) over time; 
subject-specific random effects were estimated on the intercept and 
on the slope. In ELOVL2 CpG_11.12.13.14 starting model, we 
observed no variability for the random effects on the intercept and 
on the slope of the interaction between participant and age at the 
recruitment. These two terms were therefore removed from the over-
specified starting model, resulting in the subsequent model: ELOVL2_
CpG_11.12.13.14~time*Age_at_recruitement+(0+time|Person.
ID). Analysis of variance confirmed that the two models did not 
significantly differ. The complete model for FHL2 was equivalent, 
but the only nonsignificant effect was in the random effect of the 
slope between participant and age of recruitment, leading to the final 
model: FHL2_CpG_19.20~time+Age_at_recruitement + (1|Person.
ID)+(0+time|Person.ID).
To study the association between familial longevity and ELOVL2 
and FHL2 methylation in LLS offspring and their spouses, we per-
formed linear regression, adjusted for age, gender, bisulphite date, 
and WBC counts, in STATA/SE 11.2 (StataCorp LP). Robust standard 
errors were used to account for sibship relations. Prospective analy-
sis of ELOVL2 and FHL2 methylation was performed separately 
in the LLS nonagenarians and the LLS offspring and their spouses 
using a left-truncated Cox proportional hazards model, adjusted for 
age, gender, bisulphite date, and WBC counts, in STATA/SE 11.2 
(StataCorp LP). Robust standard errors were used to account for 
sibship relations. After a mean follow-up time of 9.5 years, 92.5% 
(n = 807, LLS nonagenarians) and 6.4% (n = 147, LLS offspring and 
spouses) of the individuals had died.
To determine the association of ELOVL2 and FHL2 methylation 
with CMV infection in the LLS, we performed linear regression, sep-
arately for the LLS nonagenarians and the LLS offspring and their 
spouses, adjusted for age, gender, bisulphite date, and WBC counts, 
in STATA/SE 11.2 (StataCorp LP). Robust standard errors were used 
to account for sibship relations.
Journals of Gerontology: BIOLOGICAL SCIENCES, 2017, Vol. 72, No. 8 1017
Downloaded from https://academic.oup.com/biomedgerontology/article-abstract/72/8/1015/2630029
by guest
on 21 January 2018
Results
Association of ELOVL2 and FHL2 DNA Methylation 
With Chronological Age Across Different Cell Types 
and Tissues
As the epigenetic clock described by Horvath is a multitissue age pre-
dictor, we considered ELOVL2 and FHL2 methylation in different 
cell types from healthy individuals of different ages.
First, considering that blood is composed of different cell types 
whose relative proportion can greatly vary among individuals, we 
studied age-associated changes in ELOVL2 and FHL2 DNA meth-
ylation in blood and purified granulocytes from the same partici-
pant. EpiTYPER analysis on 92 participants aged 22 to 98  years 
showed similar methylation levels and age-dependent changes in 
blood and granulocytes (Supplementary Figure 2). Within ELOVL2, 
a group of adjacent CpG units (from CpG_8 to CpG_15.16.17) 
showed highly significant hypermethylation associated with age. 
Both in blood and granulocytes, the highest correlation was 
observed for CpG_11.12.13.14 (Supplementary Figure  2A and C; 
Spearman’s ρ  =  .91 in blood and .93 in granulocytes). A  similar 
behavior was observed for FHL2, where the region of age-associ-
ated differential methylation included CpG sites from CpG_9.10 to 
CpG_19.20 (Supplementary Figure 2B and D), with the highest val-
ues for CpG_9.10 in blood (Spearman’s ρ = .73) and in granulocytes 
(Spearman’s ρ = .71). Paired t test was used to compare DNA meth-
ylation profiles between blood and granulocyte samples from the 
same individual. Several CpG sites resulted in significantly different 
methylation profiles (p < .05), but the differences between the two 
tissues were very small (Supplementary Figure 3).
To evaluate whether ELOVL2 and FHL2 methylation correlated 
with chronological age in cell types other than blood, we measured 
their DNA methylation levels in primary DF cultures established from 
three young, three middle-aged, and four centenarian donors. Within 
ELOVL2, the group of CpG units from CpG_8 to CpG_15.16.17 
showed significant hypermethylation in DFs from centenarians com-
pared with DFs from young and middle-aged donors (Figure 1). The 
difference reached the maximum for CpG_11.12.13.14 (Student’s 
t test, p =  .017 for centenarians vs young donors comparison and 
p = .026 for centenarians vs middle-aged donor comparison), which 
was also the CpG unit that better correlated with donors’ age 
(Supplementary Figure 4; Spearman’s ρ =  .79). A similar but non-
significant trend was observed when comparing DFs from middle-
aged and young donors. DFs from centenarian and middle-aged 
donors showed high standard deviations for the CpG sites whose 
DNA methylation status is age dependent, whereas DFs from young 
donors were more homogeneous. Although the differences in stand-
ard deviations could be ascribed to the small number of observations 
and/or to different age ranges in the three groups (30–31, 58–68, 
and 100–105 years old), it is also possible to suppose that biopsies 
from older participants include cells which are more heterogeneous 
for their DNA methylation patterns. Within the FHL2 target region, 
no significant differences were observed between the three groups 
of DFs. However, a trend toward hypermethylation from young 
to centenarian donors was evident for the region spanning from 
CpG_9.10 to CpG_19.20 (Figure 1). Also in this case, DFs from cen-
tenarians displayed higher inter-individual variability than DFs from 
younger donors. CpG_16.17 was the most correlated with donors’ 
age (Supplementary Figure 4; Spearman’s ρ = .91).
To complete these results, we searched GEO DataSet reposi-
tory for Infinium 450k experiments in which DNA methylation 
was assessed in healthy human tissues (Supplementary Table 2). For 
comparison, we also considered ELOVL2 and FHL2 DNA methyla-
tion values in a whole-blood data set. We extracted β values for the 
probes mapping within the ELOVL2 and FHL2 genes (15 and 34 
probes, respectively) and calculated Spearman’s correlation with age. 
The methylation of several CpG sites correlated with age in differ-
ent tissues (Supplementary File 2). In particular, the methylation of 
cg16867657, cg21572722, and cg24724428 within ELOVL2 and 
of cg06639320, cg22454769, and cg24079702 within FHL2, which 
was previously shown to be age associated in whole blood, corre-
lated significantly with age in most tissues (Supplementary File 2). 
We focused our attention on cg16867657 (ELOVL2; Figure 2 and 
Supplementary Figure  5) and cg06639320 (FHL2; Supplementary 
Figure 6), which showed the best correlation with age in blood. For 
cg16867657, a trend toward hypermethylation was evident in most 
of the analyzed tissues and reached statistical significance in periph-
eral blood mononuclear cells, CD4 and CD8 T cells, monocytes, 
abdominal and gluteal subcutaneous adipose tissue, bone, temporal, 
frontal motor, occipital, parietal, sensory and visual cortex, frontal 
lobe white matter, cingulate gyrus hippocampus, midbrain, skel-
etal muscle, liver, dermis, epidermis, and mesenchymal stem cells. 
Figure 1. ELOVL2 and FHL2 DNA methylation profiles in dermal fibroblasts from 
young, middle-aged, and centenarian donors. Mean methylation values and 
standard deviations of the CpG sites assessed by the EpiTyper assay are reported.
Figure  2. Age-dependent hypermethylation of ELOVL2 cg16867657 in 30 
normal tissues analyzed using the Infinium 450k platform (1: whole blood; 
2: peripheral blood mononuclear cells; 3: neutrophils; 4: CD4 T cells; 5: 
CD8 T cells: 6: monocytes; 7: subcutaneous adipose tissue abdominal; 8: 
subcutaneous adipose tissue gluteal; 9: hip cartilage; 10: bone; 11: prefrontal 
cortex; 12: temporal cortex; 13: cerebellum; 14: frontal lobe white matter; 15: 
caudate nucleus; 16: cingulate gyrus; 17: frontal cortex; 18: hippocampus; 
19: midbrain; 20: motor cortex; 21: occipital cortex; 22: parietal cortex; 23: 
sensory cortex; 24: visual cortex; 25: skeletal muscle; 26: liver; 27: aortic 
tissue; 28: dermis; 29: epidermis; 30: mesenchymal stem cells). For each 
tissue, linear regression between age and DNA methylation is plotted.
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The only tissues in which we did not observe a trend toward hyper-
methylation were cerebellum and aortic tissue. A  similar scenario 
was evident for cg06639320, with the exception of neutrophilis, 
abdominal subcutaneous adipose tissue, caudate nucleus, and epi-
dermis that did not show a trend toward hypermethylation, whereas 
cerebellum and hip cartilage did. In this case, aortic tissue DNA 
methylation was also stable over time.
DNA Methylation of ELOVL2 and FHL2 in Cell 
Cultures at Different Replicative Passages
The observation that ELOVL2 and FHL2 are linearly hypermethyl-
ated with age in almost all tissues prompted us to think that the 
underlying mechanism could be linked to common cellular activities. 
A  possibility could be that methylation of the two loci is associ-
ated with cellular replication. To test this hypothesis, we measured 
ELOVL2 and FHL2 methylation by EpiTYPER in DFs during in 
vitro cell divisions. DFs from the two middle-aged donors (indi-
cated as DF1 and DF2) were expanded until medium (Passage 13, 
P13) and late (Passage 22, P22) passages. For all the ELOVL2 
CpGs tested, P3 and P13 methylation profiles were largely similar 
(Figure 3A and Supplementary Figure 7A). On the contrary, in both 
DF cultures, the region spanning from CpG_9 to CpG_15.16.17 
resulted in 10%–30% more methylation in P22 compared with 
previous passages. The correlation between DNA methylation and 
cell passage was high in both DF cultures (Supplementary Table 3), 
although it did not reach statistical significance, which may be due to 
the limited number of points taken into consideration. For the FHL2 
target region, the results of the analysis were less straightforward, 
as passage-dependent hypermethylation was evident only in DF2 
(Figure 3A and Supplementary Figure 7A).
Similar results were observed for human umbilical vein endothe-
lial cells (HUVECs), which were cultured until growth arrest 
(Passage 12) as previously described (30). The methylation of region 
enclosed between CpG_9 and CpG_15.16.17 of ELOVL2 pro-
gressively increased with cell passages (Supplementary Figure  7B). 
Spearman’s correlation was maximum for CpG_10 (Spearman’s 
ρ = .86, p = 3 × 10–4, methylation range from 2% to 32%), whereas 
CpG_11.12.13.14 showed similar hypermethylation range but lower 
correlation (Spearman’s ρ = .52). Also in this case, the passage-depend-
ent increase in FHL2 methylation retained statistical significance for 
CpG_9.10 (Spearman’s ρ = .63; p = .03), despite reduced magnitude 
(methylation range 14% to 22%, Supplementary Figure 7B).
HUVECs entered senescence approximately at Passage 9 (30), 
while methylation of ELOVL2 and, to a lesser extent, of FHL2 
already increased at lower passages. This observation suggests that 
hypermethylation of the two loci is associated with cell replication 
rather than with cellular senescence. To validate this observation, 
we measured DNA methylation of ELOVL2 and FHL2 in LF1 fetal 
lung fibroblasts at early passages, after 8 weeks in senescence (senes-
cent LF1) and after 16 weeks in senescence (deeply senescent LF1). 
EpiTYPER assay showed a striking increase in methylation level of 
ELOVL2 region enclosed from CpG_8 to CpG_15.16.17 and in 
FHL2 region enclosed from CpG_9.10 to CpG_19.20 (Figure 3B) in 
senescent cells compared with young cells. On the contrary, methyla-
tion profiles of senescent cells and deeply senescent cells were totally 
comparable, indicating that senescence progression does not affect 
per se the epigenetic status of the two loci.
Whole-Blood DNA Methylation of ELOVL2 and FHL2 
in a Longitudinal Cohort
We measured whole-blood DNA methylation levels of ELOVL2 and 
FHL2 in a cohort of 19 participants tested longitudinally at inter-
vals of 5 years, for five measurements (t1, t2, t3, t4, and t5; age at 
recruitment ranging from 22 to 57 years). We used a mixed-effects 
model including time and age at recruitment to evaluate longitudinal 
changes in methylation of ELOVL2 CpG_11.12.13.14 and FHL2 
CpG_9.10, the two CpG sites with the highest correlation values 
with age in whole blood. DNA methylation profiles confirmed time-
dependent hypermethylation of the two loci, with a clearer trend for 
ELOVL2 (Figure 4 and Supplementary Figure 8).
For ELOVL2 CpG_11.12.13.14, we found a significant associa-
tion between methylation and time (estimate = 0.016, SE = 0.0027; 
p  =  8.62 × 10–8) and age at recruitment (estimate  =  0.008, 
SE = 0.00077; p = 3.55 × 10–15). There was a significant methylation-
by-time interaction with age at recruitment (estimate = −0.00027, 
SE = 0.000065; p = 1.03 × 10–4), indicating that the slope of associa-
tion between ELOVL2 methylation and time decreases with age at 
recruitment.
Figure 3. (A) ELOVL2 and FHL2 DNA methylation profiles in dermal fibroblasts 
(DFs) from middle-aged donor 1 (DF1) at replicative Passages 3, 13, and 22. 
(B) ELOVL2 and FHL2 DNA methylation profiles in F1 fetal lung fibroblasts 
at early passages, after 8 weeks in senescence (senescent LF1) and after 16 
weeks in senescence (deeply senescent LF1).
Figure  4. Regression lines between DNA methylation of ELOVL2 
CpG_11.12.13.14 or FHL2 CpG_9.10 and age of 19 participants longitudinally 
assessed at five intervals of 5 years.
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Similarly, hypermethylation of FHL2 CpG_9.10 was associated 
with time (estimate = 0.0019, SE = 0.00038; p = 2.82 × 10–5) and age 
at recruitment (estimate = 0.003, SE = 0.00047; p = 5.19 × 10–6), but 
no interaction between the two terms was observed.
Notably, random effects on the intercept were statistically sig-
nificant in FHL2 but not in ELOVL2 model, suggesting that in the 
latter subject-specific effects were negligible.
Association Between Age, Familial Longevity, 
Mortality, and CMV Infection in the LLS and ELOVL2 
and FHL2 DNA Methylation
Whole-blood ELOVL2 and FHL2 methylation was measured in the 
LLS using EpiTYPER assay, and Spearman’s correlation with age 
was calculated for each CpG unit. Figure 5 shows the increase in 
the methylation of CpG units CpG_11.12.13.14 (ELOVL2) and 
CpG_9.10 (FHL2) with age in the LLS. As depicted in Supplementary 
Figure  9, the highest correlations in the combined group of LLS 
nonagenarians, offspring, and spouses were 0.749 (ELOVL2 
CpG_11.12.13.14) and 0.634 (FHL2 CpG_9.10 and CpG_19.20).
To determine whether the methylation levels of ELOVL2 and 
FHL2 were also associated with familial longevity, we compared 
the methylation of CpG units CpG_11.12.13.14 (ELOVL2) and 
CpG_9.10 (FHL2) between the LLS offspring and their spouses. 
Although these groups have shown a wide range of metabolism-
related differences (23) indicating a difference in metabolic health and 
biological age, the methylation levels of these CpG units did not differ 
(β = 0.27 (95% confidence interval [CI] −0.20 to 0.74), p = .257 and 
β = −0.03 (95% CI −0.33 to 0.27), p = .849, respectively), indicating 
that the methylation levels of ELOVL2 and FHL2 are not associated 
with biological age represented by familial longevity.
Next, we determined whether the methylation levels of ELOVL2 
and FHL2 associate with prospective survival at high ages (LLS 
nonagenarians (n  =  862 [798 deaths; ELOVL2] or n  =  864 [801 
deaths; FHL2]) and middle age (LLS offspring and spouses (n = 2,258 
[147 deaths; ELOVL2] or n = 2,283 [147 deaths; FHL2]). We found 
no association with survival, neither for the methylation level of 
CpG units CpG_11.12.13.14 (ELOVL2) (hazard ratio [HR] = 1.01, 
95% CI 0.99 to 1.02, p =  .445 [LLS nonagenarians]; HR = 1.01, 
95% CI 0.98 to 1.05, p = .382 [LLS offspring + spouses]) nor for 
CpG_9.10 (FHL2) (HR = 1.01, 95% CI 0.99 to 1.02, p = .486 [LLS 
nonagenarians]; HR = 1.01, 95% CI 0.95 to 1.07), p = .724 [LLS 
offspring + spouses]).
Methylation levels could be influenced by infections (31–33). 
Therefore, we determined the association of CMV serostatus with 
the methylation level of CpG units CpG_11.12.13.14 (ELOVL2) 
and CpG_9.10 (FHL2) in the LLS participants. LLS nonagenarians 
infected with CMV exhibit increased methylation levels of ELOVL2, 
comparable with an increase of ~3.5 years (β = 1.11, 95% CI 0.22 to 
1.99, p = .015) (Table 1). The association of age with the methyla-
tion level of CpG unit CpG_11.12.13.14 is not affected by adding 
CMV serostatus to the model (data not shown).
Discussion
Epigenomic studies on whole blood from individuals of different 
age were concordant in demonstrating that ELOVL2 and FHL2 
CpG islands get hypermethylated during aging. We used different 
models (publicly available DNA methylation repositories, in vitro 
cellular models and human cohorts) to explore several aspects of 
age-dependent epigenetic shift of ELOVL2 and FHL2.
First, we confirmed age-dependent hypermethylation of ELOLV2 
and FHL2 in blood and granulocytes. Then, we investigated whether 
this methylation pattern could be reproduced in other human tis-
sues. A  careful analysis of currently available Infinium 450k data 
demonstrated that this is the case, that is, ELOVL2 and FHL2 
DNA methylation increases with age in most of the analyzed tissues 
(24/30 for cg16867657 within ELOVL2 and 22/30 for cg06639320 
within FHL2). Differently from Horvath’s epigenetic clock, ELOVL2 
cg16867657 did not show any trend toward hypermethylation in cer-
ebellum. In this tissue, Horvath’s epigenetic clock predicts age with 
reasonable accuracy, although showing a slower tissue aging (34). 
Even if this point deserves deeper investigation through more repre-
sentative cohorts, these results suggest that, differently from Horvath’s 
epigenetic clock, ELOVL2 cg16867657 methylation is related to cell 
replication. Indeed, it is well established that cell turnover greatly var-
ies between different tissues: beside tissues with high proliferative rate 
(such as the hematopoietic system and the epidermis) there are tissues 
that, although not continuously replicating, have a substantial replica-
tive potential in response to injury (such as the skeletal muscle and 
the liver). Estimations of replacement rates in different tissues through 
the (14)C bomb-pulse method have shown that cell turnover occurs 
in tissues like skeletal muscle and cerebral cortex (35,36), but that is 
definitely lower in cerebellum (36), consistent with the higher ration 
neurons/glial cells compared with the other brain regions (37). These 
observations perfectly fit with the trend of age-associated hypermeth-
ylation of ELOVL2 cg16867657, which was evident in all the tissues 
but cerebellum and aortic tissue, another tissue with low replication 
rate (38). As far as it concerns FHL2, the relationship between meth-
ylation and tissue cell turnover was less straightforward. For example, 
cg06639320 methylation was age correlated in cerebellum but not in 
epidermis, a tissue with higher replication rate. This could indicate 
that FHL2 methylation is not strictly associated to cell replication and 
that it can be affected by other age-associated factors.
Figure 5. Scatterplot of age and methylation level for CpG unit CpG_11.12.13.14 
in ELOVL2 and CpG_9.10 in FHL2 in the Leiden Longevity Study. Black circles 
(blue circles online) indicate male nonagenarians, gray circles (orange circles 
online) indicate female nonagenarians, gray diamonds (green diamonds 
online) indicate male offspring, black diamonds (purple diamonds online) 
indicate female offspring, gray squares (blue squares online) indicate male 
spouses, and black squares (red squares online) indicate female spouses.
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Using two different in vitro models (DFs and HUVECs), we 
showed that the target regions within ELOVL2 and, to a lesser 
extent, FHL2 get hypermethylated with cell divisions. The increase 
in cellular methylation is not a consequence of senescence, as it is 
already evident at low-middle passages and it does not increase in 
ultra-senescent cells compared with senescent cells. Also the DNAm 
age estimated on the basis of Horvath’s epigenetic clock corre-
lates with in vitro cell passages (10), confirming that cell division 
is tracked by methylation of multiple CpG sites within the genome 
(39–41). However, as aforementioned, Horvath’s epigenetic clock is 
not a measure of mitotic age, as it tracks age in nonproliferative tis-
sues such as cerebellum (10).
We used a cohort of 19 participants, assessed every 5 years for 
20  years, to evaluate intra-individual changes of ELOVL2 and 
FHL2 methylation over time. Consistently with previous results, 
participants displayed a progressive hypermethylation of ELOVL2 
with time, while they were more heterogeneous regarding FHL2 
changes in methylation.
Several studies, carefully gathered in a recent review (42), suggest 
that the number of cell divisions within a tissue affects aging, with a 
decrease in division rate contributing to extend life span. Therefore, 
we evaluated if DNA methylation of ELOVL2 and FHL2 CpG 
islands was associated with longevity and/or mortality in the LLS 
cohort. We previously demonstrated that LLS offspring are metabol-
ically healthier and biologically younger than their spouses in terms 
of morbidity prevalence (23,24). However, ELOVL2 and FHL2 
methylation levels did not show significant differences between 
nonagenarian siblings and their partners. Then we tested ELOVL2 
and FHL2 methylation status at baseline for association with pro-
spective mortality across two generations in LLS families, but also 
in this case we did not find a significant association. Collectively, 
these results indicate that ELOVL2 and FHL2 methylation is not 
associated with longevity/mortality in the LLS. In previous studies, 
Horvath’s and Hannum’s age predictors have been successfully asso-
ciated with physical/cognitive fitness and mortality and have there-
fore been proposed as reliable markers of biological age (12–15). 
However, it must be considered that the mean age of the cohorts 
analyzed by Marioni and colleagues and Christensen and colleagues 
ranges from 66 to 79 and 33 to 76 years, respectively, and it is there-
fore definitely lower than that of nonagenarians (94 years). It is con-
ceivable that the performance of a biomarker in predicting mortality 
can vary according to the baseline age of individuals, and therefore 
our results are not directly comparable with those of Marioni and 
colleagues. Recently telomere length, which is a marker of cell rep-
lication, has been investigated in the LLS (27). Leukocyte telomere 
length did not differ between middle-aged LLS offspring and their 
spouses, but it was significantly associated with mortality. However, 
it must be considered that age-associated telomere shortening could 
be a consequence not only of DNA replication during cell divisions, 
but also of accumulation of oxidative stress (43), which on the con-
trary could not affect ELOVL2 methylation. This consideration 
could explain why different markers of cell replication could provide 
different results when correlated to mortality.
Importantly, the hypothesis that the increase in ELOVL2 meth-
ylation occurs with cell replication fits well with the observation 
that in LLS nonagenarians ELOVL2 is hypermethylated in indi-
viduals infected with CMV. Chronic CMV infection leads to oli-
goclonal expansion of CD8+ T cells which tend to accumulate in 
megaclones, filling the immunological space at the expense of the 
TCR repertoire for other antigens (44,45). Therefore, ELOVL2 
hypermethylation in CMV-positive nonagenarians could be 
informative of a higher number of replication events in a fraction 
of WBC.
In a previous study, Kim and colleagues demonstrated that 
hypermethylation of Nkx2-5 in endometrium mirrored somatic 
cell divisions and assumed that the observed changes were the 
result of stochastic error (46). At present, we are not able to say if 
the progressive increase of cells methylated in ELOVL2 and FHL2 
CpG island with age is part of a developmental program (47) or 
a stochastic event. It is reasonable to suppose that, at least for 
ELOVL2, DNA methylation occurs in concomitance with DNA 
replication. Dnmt1 has been shown to interact with the replication 
machinery (48–50) and, although it has been classically considered 
a maintenance methyltransferase, it has been shown to have also de 
novo activity both in vitro and in vivo (51). While Dnmt1 activity 
decreases during in vitro replication of WI-38 fibroblasts, Dnmt3b 
shows the opposite trend (52,53) and could therefore have a role in 
hypermethylation of ELOVL2 with cellular passages. The fact that 
ELOVL2 hypermethylation occurs in several tissues suggests that 
this genomic region has a chromatin structure with a given prob-
ability of being target of methyltransferase activity throughout cell 
replications (54,55).
In conclusion, we suggest that methylation of ELOVL2 could be 
a calculator (monitor) of cell divisions. Further investigations should 
clarify the biological relevance of this clock, in particular in the con-
text of aging cells and organisms.
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Table 1. Association of CpG_11.12.13.14 (ELOVL2) and CpG_9.10 (FHL2) Methylation With CMV Infection
LLS Offspring + Spouses LLS Nonagenarians
Parameter n β SE 95% CI p n β SE 95% CI p
CpG_11.12.13.14 CMV infection 2,131 0.35 0.25 −0.13 to 0.84 .15 790 1.11 0.45 0.22 to 1.99 .01
CpG_9.10 CMV infection 2,155 −0.05 0.14 −0.33 to 0.23 .74 792 0.15 0.35 −0.54 to 0.85 .66
Note: 95% CI = 95% confidence interval; CMV = cytomegalovirus; LLS = Leiden Longevity Study; SE = standard error.
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